Correlation Between Akari Therapeutics and Marizyme

Can any of the company-specific risk be diversified away by investing in both Akari Therapeutics and Marizyme at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Akari Therapeutics and Marizyme into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Akari Therapeutics PLC and Marizyme, you can compare the effects of market volatilities on Akari Therapeutics and Marizyme and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Akari Therapeutics with a short position of Marizyme. Check out your portfolio center. Please also check ongoing floating volatility patterns of Akari Therapeutics and Marizyme.

Diversification Opportunities for Akari Therapeutics and Marizyme

-0.1

Correlation Coefficient

Akari Therapeutics  Marizyme

Good diversification

The 3 months correlation between Akari and Marizyme is -0.1. Overlapping area represents the amount of risk that can be diversified away by holding Akari Therapeutics PLC and Marizyme in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Marizyme and Akari Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Akari Therapeutics PLC are associated (or correlated) with Marizyme. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Marizyme has no effect on the direction of Akari Therapeutics i.e., Akari Therapeutics and Marizyme go up and down completely randomly.

Pair Corralation between Akari Therapeutics and Marizyme

Given the investment horizon of 90 days Akari Therapeutics PLC is expected to under-perform the Marizyme. But the stock apears to be less risky and, when comparing its historical volatility, Akari Therapeutics PLC is 3.03 times less risky than Marizyme. The stock trades about -0.04 of its potential returns per unit of risk. The Marizyme is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  91.00  in Marizyme on September 1, 2024 and sell it today you would lose (86.00) from holding Marizyme or give up 94.51% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	99.8%
Values	Daily Returns

Akari Therapeutics PLC  vs.  Marizyme

Akari Therapeutics PLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Akari Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Marizyme

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Marizyme are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Marizyme displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Akari Therapeutics and Marizyme

The main advantage of trading using opposite Akari Therapeutics and Marizyme positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Akari Therapeutics position performs unexpectedly, Marizyme can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marizyme will offset losses from the drop in Marizyme's long position.

The idea behind Akari Therapeutics PLC and Marizyme pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.